Quick answer: Most synthetic peptides purified by reversed-phase HPLC are isolated as trifluoroacetate salts, because TFA is commonly used as the ion-pairing agent in the mobile phase. "TFA removed" usually indicates that a counterion-exchange or related purification step has been performed to reduce trifluoroacetate and obtain the material predominantly in another specified form. It does not by itself establish complete exchange, a single-counterion composition, or any particular residual-TFA level. The material should therefore be described by the specified salt form together with measured counterion and residual-TFA results on a stated basis — and because exchange is process work, it should be confirmed commercially before quotation.
Salt form is one of the most under-specified fields in peptide procurement. It rarely appears in a catalogue listing, it often appears on a COA only if someone asked, and it quietly changes both what the material is and what a gram of it is worth.
This guide is for procurement, QA, and R&D teams defining a qualified B2B project. It is a specification and analytical-documentation reference. It does not establish that any material is sterile, endotoxin-controlled, pharmaceutical grade, suitable for injection, or approved for human use, and it does not provide dosing or medical guidance.
1. Where the TFA comes from
Trifluoroacetic acid is not an additive someone chose to leave in. It is a consequence of how peptides are commonly made and purified.
In standard solid-phase synthesis and reversed-phase HPLC purification, TFA is widely used in the mobile phase as an ion-pairing agent because it improves peak shape and resolution. When the purified peptide is collected and lyophilized, trifluoroacetate is associated with its charged sites. The peptide is therefore, by default, a TFA salt.
This is normal, expected, and disclosed by any supplier who understands their own process. The question is not whether TFA was involved. It is what remains in the delivered material, and whether that is compatible with the buyer's downstream work.
2. What "TFA removed" can and cannot establish
Buyers request TFA-removed material for two distinct reasons, and it is worth separating them because they lead to different specifications.
Downstream compatibility. Some research workflows specify a counterion other than trifluoroacetate. Whether that applies is a decision for the buyer's own protocol and internal requirements. The supplier's job is to meet and document the stated specification, not to advise on its necessity.
Mass-basis stability. Counterion content occupies part of the mass of the material and varies with the peptide and the process. A buyer standardizing on a defined salt form is also standardizing the basis on which milligrams are counted. That connection is developed in the companion article, What a 10mg Peptide Vial Actually Contains.
The boundary matters. An exchange step reduces trifluoroacetate and shifts the material predominantly toward the specified form. It does not automatically produce a single-counterion product: residual TFA may remain, and a mixed counterion composition is possible. Exchange efficiency and the resulting composition are analytical questions, not process intentions. The meaningful specification is therefore a measured residual-TFA result and a measured counterion content on stated methods and bases — not an absolute absence claim.
3. Which salt forms are applicable
Salt-form feasibility cannot be assigned from a simple "basic peptide versus acidic peptide" label. Many peptides contain both acidic and basic sites, and the isolated form depends on sequence, terminal modifications, formulation pH, degree of protonation or neutralization, purification history, and the intended product specification.
In general terms:
- Where positively charged sites are present, anionic counterions such as trifluoroacetate, acetate, or chloride may be associated with the peptide.
- Where acidic groups are neutralized, cations such as sodium may be present.
- The number and proportion of counterions are product- and process-dependent, and should be confirmed analytically rather than derived from the sequence.
This is why a request such as "sodium salt for one product and acetate for the other two" is a reasonable buyer specification rather than a contradiction: different molecules, different ionizable sites, different applicable forms. It is also why a supplier should confirm feasibility per peptide instead of accepting every salt-form request across a whole order.
One terminology note that shows up on documents: a product may be named as a hydrochloride salt, but the analytical test that supports it is a chloride content determination. Naming and measurand are not the same field, and a specification should be clear about both.
WUMO's practical position: acetate and chloride-containing forms are among the alternatives commonly requested when buyers want reduced-TFA material, and they are what WUMO's technical work usually involves. For any specific peptide, WUMO confirms the technically feasible salt form, exchange route, analytical scope, price, and lead time separately per product and project, rather than treating a general capability as a per-product commitment.
4. How salt form is verified
A stated salt form on a specification sheet is an intention. A measured counterion result is evidence.
Counterion analysis is the established method family for this. Commonly used approaches include ion chromatography for anions such as acetate, chloride, and trifluoroacetate, and fluorine-specific techniques such as ¹⁹F NMR in the trifluoroacetate case. What a buyer should confirm is not the instrument brand but the reporting basis:
- Which counterion was measured, and by which method?
- Is the result reported for the batch being supplied, or for a representative sample?
- What is the calculation basis — percentage of total mass, molar ratio, as-is or dried basis?
- Where residual TFA is specified, is there a stated numerical result with its method, rather than a blanket "TFA free" statement?
- Is there any indication of mixed counterion composition, and is that acceptable under the specification?
The phrase "TFA removed" alone is not sufficient analytical evidence for a batch-specific salt-form claim. Buyers should request the specified counterion, the analytical method, the reporting basis, the residual-TFA result, and the linkage between those results and the supplied lot.
For how identity, purity, and content sit alongside counterion results in the same document package, see Peptide COA, HPLC, and LC-MS Documentation Review.
5. What salt form changes commercially
Salt form is not a free option box. It touches four commercial variables at once.
| Variable | Effect |
|---|---|
| Price | Counterion exchange is additional process work with its own yield consequences. It should be confirmed at quotation rather than assumed. |
| Lead time | An additional processing and analytical step can extend the schedule, particularly for a first project. |
| Mass basis | Different counterions carry different mass, so the peptide content per gram of material changes with the salt form. |
| Documentation | Counterion analysis and a residual-TFA result are added analytical scope, and should be named in the RFQ so the supplier can price them. |
Salt form also changes how a labeled milligram figure should be read, and it interacts with the excipient system and cake behavior in a lyophilized presentation. For that side of the specification, see Why Some Lyophilized Peptide Cakes Hold and Others Collapse.
The practical consequence for procurement: a quotation for acetate-form material with counterion analysis and a quotation for default TFA-salt material without it are not two prices for the same thing. Normalize the specification before you normalize the price.
6. RFQ language that works
Replace "TFA free" with a specification a supplier can execute and document:
| RFQ field | What to state |
|---|---|
| Required salt form | The counterion required per product, or a request that the supplier state and support the form actually supplied. |
| Residual TFA | That a measured residual-TFA result is required on the COA, with the method and reporting basis stated. |
| Counterion content | That counterion content is to be reported, with the method and calculation basis stated. |
| Mixed composition | Whether a mixed counterion composition is acceptable, and within what limits. |
| Batch linkage | Whether results must be for the supplied lot or may be representative. |
| Feasibility confirmation | A request that the supplier confirm salt-form feasibility per peptide before quoting, rather than accepting the request across the whole order. |
| Commercial acknowledgement | That any price or lead-time effect of the salt form is stated in the quotation. |
7. Red flags
None of these establishes that a supplier is acting in bad faith. Each is a documentation gap worth closing before a deposit.
- "TFA free" is claimed with no residual-TFA result and no method behind it.
- Salt form appears nowhere in the quotation, specification sheet, or COA.
- The same salt form is accepted for every product in a multi-product request with no per-peptide feasibility comment.
- A counterion figure is given with no method, no reporting basis, and no lot linkage.
- The quotation does not state whether salt conversion and the requested counterion testing are included in scope.
- HPLC purity is offered as evidence that the salt form is correct. The two are unrelated measurements.
Frequently Asked Questions
Why do synthetic peptides usually come as TFA salts?
Trifluoroacetic acid is commonly used as an ion-pairing agent in reversed-phase HPLC purification because it improves peak shape and resolution. When the purified peptide is lyophilized, trifluoroacetate remains associated with its charged sites, so the material is isolated as a TFA salt by default.
What does "TFA removed" actually mean?
It usually indicates that a counterion-exchange or related purification step has been performed to reduce trifluoroacetate and obtain the material predominantly in another specified form, such as acetate. It does not by itself establish complete exchange, a single-counterion composition, or any particular residual level. A measured residual-TFA result and counterion content, on stated methods and bases, are what support the claim.
Can a peptide be supplied as a sodium salt?
Sometimes. Counterions associate with the peptide's charged sites, so a cation such as sodium is applicable where acidic groups are neutralized. Feasibility depends on the sequence, terminal modifications, and process, and should be confirmed per peptide before quotation rather than assumed across a whole order.
How is salt form verified?
By counterion analysis. Commonly used approaches include ion chromatography for anions such as acetate, chloride, and trifluoroacetate, and fluorine-specific methods such as ¹⁹F NMR for trifluoroacetate. Confirm which counterion was measured, by which method, on which batch, and on what calculation basis.
Is "hydrochloride salt" the same as a chloride test?
They are related but not identical fields. A product may be named as a hydrochloride salt, while the analytical result supporting it is a chloride content determination. A specification should state both the product salt name and the measurand used to confirm it.
Does HPLC purity tell me the salt form?
No. HPLC purity describes the chromatographic profile under a defined method. Salt form is established by counterion analysis. Neither result substitutes for the other.
Does changing the salt form change the price?
Usually. Counterion exchange is additional process work with its own yield and analytical consequences, and it may extend lead time. It should be confirmed commercially at quotation rather than treated as a free specification option.
Does salt form change how much peptide is in a gram of material?
Yes. Different counterions carry different mass, so the peptide content per gram changes with the salt form. This is one reason a quotation should state both the salt form and the labeling basis before prices are compared.
Should residual TFA appear on every COA?
It is a project-defined test rather than an automatic entry on every catalogue COA. Where a project depends on it, state it in the RFQ so the supplier can confirm scope, method, and any effect on price and lead time.
Specify the salt form before you compare the quote
If your project requires a defined counterion, state the required salt form per product, whether a mixed composition is acceptable, the residual-TFA and counterion results you need on the COA, and whether those results must be batch-specific. WUMO can confirm feasibility per peptide and the applicable analytical scope before issuing a formal quotation.